Study Of Fluticasone Propionate/Salmeterol In Asthmatic Subjects
Asthma

About this trial
This is an interventional treatment trial for Asthma focused on measuring asthma, allergen challenge, IL-5, eosinophils
Eligibility Criteria
Inclusion Criteria:
- Informed consent.
- Outpatient.
- Male or non-pregnant/non-lactating female.
- Aged 18-55.
- Diagnosis of asthma.
- Pre-bronchodilatory FEV1 > 75% predicted.
- Using inhaled short-acting beta-2-agonists (SABA) with no inhaled corticosteroids.
- Judged capable of withholding SABA for at least 6 hours prior to visits.
- Reversibility of >12% and 200mL or PC20 of <8mg/mL.
- Demonstration of atopy
Exclusion Criteria:
- History of life-threatening asthma.
- Use of proscribed asthma medications.
- Use of anti-histamines or potent inhibitors of CYP3A4.
- Respiratory tract infection.
- Asthma exacerbation with 4 weeks of Visit 1.
- Subjects with exercise induced asthma only.
- Concurrent respiratory disease.
- Other clinically significant, uncontrolled condition or disease.
- Use of any investigational drug within 30 days.
- Allergic to beta-2-agonists, inhaled corticosteroids or excipients.
- Positive pregnancy test.
- Using immunosuppressive medications.
- Milk protein allergy.
- Factors likely to interfere with attendance.
- Current smokers or ex-smokers with a history of >10 pack years.
- Affiliation wih Investigator site.
- Medications that may affect the course of asthma or interact with sympathomimetic amines.
Sites / Locations
- GSK Investigational Site
- GSK Investigational Site
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Sequence 1: FP, SFC, Placebo
Sequence 2: Placebo, SFC, FP
Sequence 3: SFC, FP, Placebo
Sequence 4: SFC, Placebo, FP
Sequence 5: FP, Placebo, SFC
Sequence 6: Placebo, FP, SFC
Fluticasone Propionate (FP) 100 micrograms (mcg) twice daily (BID) in the first treatment period: Salmeterol/Fluticasone Propionate Combination (SFC) 50/100 mcg BID in the second treatment period: Placebo in the third treatment period
Placebo in the first treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the second treatment period: Fluticasone Propionate 100 mcg BID in the third treatment period
Salmeterol/Fluticasone Propionate 50/100 Combination mcg BID in the first treatment period: Fluticasone Propionate 100 mcg BID in the second treatment period: Placebo in the third treatment period
Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the first treatment period: Placebo in the second treatment period: Fluticasone Propionate 100 mcg BID in the third treatment period
Fluticasone Propionate 100 mcg BID in the first treatment period: Placebo in the second treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the third treatment period
Placebo in the first treatment period: Fluticasone Propionate 100 mcg BID in the second treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the third treatment period